We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+25.69%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.85B
AUM Growth
+$604M
Cap. Flow
+$513M
Cap. Flow %
18.04%
Top 10 Hldgs %
65.03%
Holding
69
New
10
Increased
6
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
TIL icon
Instil Bio
TIL
+$320M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$126M
3
TERN
Terns Pharmaceuticals
TERN
+$58.6M
4
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$35.9M
5
DSGN icon
Design Therapeutics
DSGN
+$17.9M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$20.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$18.5M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$17M
4
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$10.2M
5
MTNB icon
Matinas BioPharma
MTNB
+$8.77M

Sector Composition

Rank Sector Weight
1 Healthcare 85.49%
2 Materials 8.84%
3 Financials 5.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
1
Instil Bio
TIL
$49.4M
$313M 11.01%
+624,339
New +$320M
ALXO icon
2
ALX Oncology
ALXO
$268M
$311M 10.94%
4,220,048
– –
AMRS
3
DELISTED
Amyris Inc.
AMRS
$251M 8.84%
13,161,847
– –
ASND icon
4
Ascendis Pharma A/S
ASND
$16.7B
$214M 7.54%
1,664,242
-133,503
-7% -$20.3M
NFH
5
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$162M 5.68%
14,300,000
– –
HRMY icon
6
Harmony Biosciences
HRMY
$2.07B
$150M 5.27%
4,534,341
– –
GTH
7
DELISTED
Genetron Holdings Limited ADS
GTH
$136M 4.78%
2,113,287
– –
BOLT icon
8
Bolt Biotherapeutics
BOLT
$7.72M
$127M 4.48%
+193,565
New +$126M
TARS icon
9
Tarsus Pharmaceuticals
TARS
$2.57B
$105M 3.68%
3,245,035
– –
ALGS icon
10
Aligos Therapeutics
ALGS
$26.3M
$80.7M 2.83%
141,881
– –
LEGN icon
11
Legend Biotech
LEGN
$3.68B
$80M 2.81%
2,755,007
– –
EPIX
12
DELISTED
ESSA Pharma
EPIX
$60.1M 2.11%
2,068,907
+175,000
+9% +$4.07M
TERN
13
DELISTED
Terns Pharmaceuticals
TERN
$58.9M 2.07%
+2,675,133
New +$58.6M
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
$47.9M 1.68%
1,863,296
+245,000
+15% +$6.44M
ACRS icon
15
Aclaris Therapeutics
ACRS
$744M
$41.5M 1.46%
1,647,214
– –
OLMA icon
16
Olema Pharmaceuticals
OLMA
$1.01B
$41.1M 1.44%
1,238,575
– –
SVA
17
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 1.34%
5,900,000
– –
ISEE
18
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$36.9M 1.3%
5,966,527
– –
CRNX icon
19
Crinetics Pharmaceuticals
CRNX
$8.88B
$33.8M 1.19%
2,214,138
-121,751
-5% -$1.89M
SRRA
20
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$33M 1.16%
1,917,074
– –
NVAX icon
21
Novavax
NVAX
$1.21B
$28.6M 1%
157,487
– –
CLDX icon
22
Celldex Therapeutics
CLDX
$2.79B
$26.6M 0.94%
1,291,875
– –
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
$26.6M 0.93%
2,937,093
-589,000
-17% -$4.76M
VRNA
24
DELISTED
Verona Pharma
VRNA
$25.5M 0.9%
3,048,507
– –
PASG icon
25
Passage Bio
PASG
$14.7M
$24.7M 0.87%
70,675
-3,677
-5% -$1.57M
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Vivo Capital held 69 positions worth $2.85B, up 27% from $2.24B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Vivo Capital deployed $513M of net new capital in Q1 2021, opening 10 new positions and adding to 6 existing holdings. Its largest new stake was Instil Bio: 624,339 shares worth $313M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier, followed by Materials and Financials.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $20.3M trimmed.

  • Vivo Capital's largest Q1 2021 buy was Instil Bio: 624,339 shares worth $313M.
  • Vivo Capital added most to KalVista Pharmaceuticals in Q1 2021, an estimated $6.44M increase.
  • Vivo Capital's biggest Q1 2021 reduction was Ascendis Pharma A/S, cutting an estimated $20.3M.
  • Vivo Capital fully exited Rocket Pharmaceuticals in Q1 2021, selling an estimated $17M.
  • Vivo Capital's ten largest holdings make up 65% of its $2.85B portfolio in Q1 2021.
  • Vivo Capital opened 10 new positions and closed 6 in Q1 2021.
  • Vivo Capital's portfolio value rose 27% quarter-over-quarter to $2.85B.

Based on Vivo Capital's 13F filing for Q1 2021, filed 17 May 2021.